ETFs with Yields Above 10% Tap Diverse Strategies Today
Three ETFs with yields above 10% are drawing attention in March 2026, each using a different mechanism to pay out hig...
Zero Based Budgeting For Debt Reduction
Zero Based Budgeting targets debt by prioritizing principal payments and efficient allocations, accelerating payoff timelines.
19,225 articlesUber Stock Down Just: Is This a Buy Opportunity Now?
Uber stock has slipped about 12% in three months, trading near $74 after a strong run. This article breaks down what’...
Solar Stock Down Year: Big Bet Signals Opportunity
When a solar stock down year meets a bold 75 million bet on Enphase Energy, investors gain a rare glimpse into how co...
Education Stock Fund Stake Surges 84%: What It Means
A fund boosted its education exposure by 84%, pushing its stake toward the $6 million mark. This article breaks down ...
QuantumScape Stock Down 63%: Is It Time to Buy for the Long Haul?
QuantumScape faces a volatile path from lab breakthroughs to mass production. This guide breaks down what the stock d...
Can Retirees Claim Senior Deduction If They Aren’t on Social Security?
Many seniors assume you must collect Social Security to get tax relief, but that isn’t always true. Here’s how the ne...
Why Your Electricity Bill Keeps Rising—And What to Do
Household energy costs are climbing beyond inflation as grid upgrades meet rising demand. This report breaks down the...
Falling BWET 27.5% These ETFs Stand Out as S&P Dips
BWET jumps 27.5% in the past month even as the S&P 500 declines, with UNG also rising and FCG offering a different ex...
LyondellBasell Stock Soaring: Late Entry Question
LyondellBasell shares have surged about 74% year-to-date, trading near $75 as of mid-March 2026. The rally comes desp...
Morning Minute: Bitcoin Rebounds as Oil Falls Sharply
Bitcoin is showing resilience as oil prices retreat, pointing to a possible shift in risk sentiment. This morning min...
Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
APM’s Michael Banner: HECM for Purchase Struggles Now
APM’s Michael Banner says HECM for Purchase has failed to take off due to industry shortcomings rather than product f...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status